Log in

NASDAQ:BCLIBrainstorm Cell Therapeutics Stock Price, Forecast & News

$9.08
+0.58 (+6.82 %)
(As of 06/5/2020 04:00 PM ET)
Add
Compare
Today's Range
$8.44
Now: $9.08
$9.44
50-Day Range
$5.28
MA: $6.27
$8.50
52-Week Range
$3.43
Now: $9.08
$10.00
Volume797,142 shs
Average Volume404,121 shs
Market Capitalization$267.32 million
P/E RatioN/A
Dividend YieldN/A
Beta1.09
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of central nervous system (CNS) adult stem cell therapies designed to address the unmet medical needs of patients with debilitating neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes a patient's own cells, which are engineered outside the body, to produce and secrete factors known to promote neuronal survival. It is developing NurOwn for various neurodegenerative diseases, including its lead indication, which is in Phase III clinical trial for the treatment of amyotrophic lateral sclerosis, as well as in preclinical trial for the treatment of multiple sclerosis, Parkinson's disease, Huntington's disease, and autism spectrum disorder. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004 to reflect its new line of business in the development of novel cell therapies for neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in New York, New York.
Read More
Brainstorm Cell Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.01 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BCLI
CUSIPN/A
Phone201-488-0460

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value($0.54) per share

Profitability

Net Income$-23,250,000.00

Miscellaneous

Employees31
Market Cap$267.32 million
Next Earnings Date8/11/2020 (Estimated)
OptionableOptionable

Receive BCLI News and Ratings via Email

Sign-up to receive the latest news and ratings for BCLI and its competitors with MarketBeat's FREE daily newsletter.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) Frequently Asked Questions

How has Brainstorm Cell Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Brainstorm Cell Therapeutics' stock was trading at $6.68 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, BCLI stock has increased by 35.9% and is now trading at $9.08. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Brainstorm Cell Therapeutics?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Brainstorm Cell Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Brainstorm Cell Therapeutics.

When is Brainstorm Cell Therapeutics' next earnings date?

Brainstorm Cell Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for Brainstorm Cell Therapeutics.

How were Brainstorm Cell Therapeutics' earnings last quarter?

Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI) issued its earnings results on Thursday, May, 7th. The biotechnology company reported ($0.32) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.23) by $0.09. View Brainstorm Cell Therapeutics' earnings history.

What price target have analysts set for BCLI?

1 brokers have issued 1-year price objectives for Brainstorm Cell Therapeutics' shares. Their forecasts range from $9.00 to $9.00. On average, they expect Brainstorm Cell Therapeutics' stock price to reach $9.00 in the next twelve months. This suggests that the stock has a possible downside of 0.9%. View analysts' price targets for Brainstorm Cell Therapeutics.

Has Brainstorm Cell Therapeutics been receiving favorable news coverage?

News articles about BCLI stock have trended somewhat positive on Saturday, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Brainstorm Cell Therapeutics earned a media sentiment score of 2.0 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the next few days. View the latest news aboutBrainstorm Cell Therapeutics.

Are investors shorting Brainstorm Cell Therapeutics?

Brainstorm Cell Therapeutics saw a increase in short interest in April. As of April 30th, there was short interest totaling 2,290,000 shares, an increase of 22.5% from the April 15th total of 1,870,000 shares. Based on an average daily trading volume, of 754,300 shares, the days-to-cover ratio is currently 3.0 days. Approximately 10.8% of the company's shares are sold short. View Brainstorm Cell Therapeutics' Current Options Chain.

Who are some of Brainstorm Cell Therapeutics' key competitors?

What other stocks do shareholders of Brainstorm Cell Therapeutics own?

Who are Brainstorm Cell Therapeutics' key executives?

Brainstorm Cell Therapeutics' management team includes the following people:
  • Dr. Irit Arbel, Founder & Chairperson (Age 59)
  • Mr. Chaim Lebovits, Pres & CEO (Age 48)
  • Mr. Eyal Rubin, CFO & Treasurer (Age 43)
  • Dr. Ralph Z. Kern, COO & Chief Medical Officer (Age 61)
  • Mr. Uri Yablonka, Exec. VP, Chief Bus. Officer & Director (Age 42)

What is Brainstorm Cell Therapeutics' stock symbol?

Brainstorm Cell Therapeutics trades on the NASDAQ under the ticker symbol "BCLI."

Who are Brainstorm Cell Therapeutics' major shareholders?

Brainstorm Cell Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (1.46%), Raymond James & Associates (0.77%), Geode Capital Management LLC (0.58%), EAM Investors LLC (0.44%), Phoenix Holdings Ltd. (0.40%) and WINTON GROUP Ltd (0.26%). Company insiders that own Brainstorm Cell Therapeutics stock include Irit Arbel, June Sherie Almenoff, Preetam Shah and Ralph Dr Kern. View institutional ownership trends for Brainstorm Cell Therapeutics.

Which major investors are buying Brainstorm Cell Therapeutics stock?

BCLI stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., EAM Investors LLC, Phoenix Holdings Ltd., Raymond James & Associates, JPMorgan Chase & Co., Abner Herrman & Brock LLC, Geode Capital Management LLC, and Steward Partners Investment Advisory LLC. Company insiders that have bought Brainstorm Cell Therapeutics stock in the last two years include June Sherie Almenoff, Preetam Shah, and Ralph Dr Kern. View insider buying and selling activity for Brainstorm Cell Therapeutics.

How do I buy shares of Brainstorm Cell Therapeutics?

Shares of BCLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Brainstorm Cell Therapeutics' stock price today?

One share of BCLI stock can currently be purchased for approximately $9.08.

How big of a company is Brainstorm Cell Therapeutics?

Brainstorm Cell Therapeutics has a market capitalization of $267.32 million. The biotechnology company earns $-23,250,000.00 in net income (profit) each year or ($1.06) on an earnings per share basis. Brainstorm Cell Therapeutics employs 31 workers across the globe.

What is Brainstorm Cell Therapeutics' official website?

The official website for Brainstorm Cell Therapeutics is www.brainstorm-cell.com.

How can I contact Brainstorm Cell Therapeutics?

Brainstorm Cell Therapeutics' mailing address is 1325 AVENUE OF AMERICAS 28TH FLOOR, NEW YORK NY, 10019. The biotechnology company can be reached via phone at 201-488-0460 or via email at [email protected]

This page was last updated on 6/6/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.